Corcept Therapeutics Overview

  • Founded
  • 1998

Founded
  • Status
  • Public

  • Employees
  • 238

Employees
  • Stock Symbol
  • CORT

Stock Symbol
  • Share Price
  • $27.46

  • (As of Thursday Closing)

Corcept Therapeutics General Information

Description

Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.

Contact Information

Website
www.corcept.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Stock Exchange
NAS
Primary Office
  • 149 Commonwealth Drive
  • Menlo Park, CA 94025
  • United States
+1 (650) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Corcept Therapeutics Stock Performance

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$27.46 $27.01 $15.82 - $29.93 $2.94B 107M 703K $1.01

Corcept Therapeutics Financials Summary

In Thousands,
USD
TTM 30-Jun-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 2,183,931 1,925,663 2,613,322 1,151,922
Revenue 392,027 365,978 353,874 306,486
EBITDA 134,135 127,544 130,439 113,777
Net Income 112,733 112,512 106,011 94,181
Total Assets 496,364 423,756 571,731 412,312
Total Debt 2,264 526 2,551 3,461
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Corcept Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Corcept Therapeutics‘s full profile, request access.

Request a free trial

Corcept Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medica
Pharmaceuticals
Menlo Park, CA
238 As of 2021
00000
00000000000 00000

000000

or incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation u
0000000000000
Pasadena, CA
000 As of 0000
00.000
000000 - 000 00.000

000000

amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua
000000000000000
Ann Arbor, MI
000 As of 0000
00000
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Corcept Therapeutics Competitors (25)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Arrowhead Pharmaceuticals Corporation Pasadena, CA 000 00.000 000000 - 000 00.000
00000000 000000000 Formerly VC-backed Ann Arbor, MI 000 00000 00000000000 00000
000000 00000000000 Formerly VC-backed Boston, MA 00 00000 000000000 00000
000000000 00000000 Formerly VC-backed San Diego, CA 000 00000 000000000 00000
00000000 000000000 Formerly VC-backed Switzerland 00 00000 000000000 00000
You’re viewing 5 of 25 competitors. Get the full list »

Corcept Therapeutics Patents

Corcept Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20210369689-A1 Concomitant administration of glucocorticoid receptor modulator relacorilant and cyp2c9 substrates Pending 27-May-2020 0000000000
US-20220184061-A1 Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxel, a dual substrate of cyp2c8 and cyp3a4 Pending 27-May-2020 00000000000
US-20210369690-A1 Concomitant administration of glucocorticoid receptor modulator relacorilant and cyp2c8 substrates Pending 27-May-2020 00000000000
US-20210369700-A1 Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxel, a dual substrate of cyp2c8 and cyp3a4 Granted 27-May-2020 000000000
US-11285145-B2 Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxel, a dual substrate of cyp2c8 and cyp3a4 Active 27-May-2020 A61P35/00 00
To view Corcept Therapeutics’s complete patent history, request access »

Corcept Therapeutics Executive Team (12)

Name Title Board Seat Contact Info
Joseph Belanoff MD Chief Executive Officer & Founder
Charles Robb JD Chief Business Officer
Hazel Hunt Ph.D Chief Scientific Officer
Atabak Mokari Chief Financial Officer, Finance & Treasurer, Finance
Joseph Lyon Chief Accounting Officer
You’re viewing 5 of 12 executive team members. Get the full list »

Corcept Therapeutics Board Members (12)

Name Representing Role Since
Daniel Swisher Jr. Self Board Member 000 0000
David Mahoney Self Board Member 000 0000
George Baker Jr. Corcept Therapeutics Board Member 000 0000
Gillian Cannon Ph.D Self Board Member 000 0000
Gregg Alton JD Self Board Member 000 0000
You’re viewing 5 of 12 board members. Get the full list »

Corcept Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial